Rob Dillard

DocwireNews

The drug combination of niraparib (ZEJULA) and pembrolizumab (KEYTRUDA) shows promising antitumor activity in patients with advanced metastatic triple-negative breast cancer (TNBC), according to a study <a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2735888">published</a> in JAMA Oncology.In this open-label, single-arm, phase II study, researchers recruited 55 patients with advanced or metastatic TNBC regardless of BRCA mutation status or programmed death-ligand 1 (PD-L1) expression from 34 locations across the US. Following enrollment, patients were administered 200 mg of niraparib orally once daily in conjunction with 200 mg of intravenous pembrolizumab on day one of a series of 21-day cycles. The primary outcome in this study was the objective response rate (ORR) using the Response Evaluation Criteria in Solid Tumors, version one. Secondary outcomes included safety, disease control rate (DCR; complete response&thinsp;plus&thinsp;partial response&thinsp;plus&thinsp;stable disease), duration of response (DOR), progression-free survival (PFS), and overall survival. The researchers aggregated data from January 3, 2017 through October 29, 2018 and analyzed the data from October 29, 2018 through February 27, 2019.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Combo of PARP inhibitor niraparib w pembrolizumab immunotherapy in pts w adv triple-negative <a href="https://twitter.com/hashtag/BreastCancer?src=hash&amp;ref_src=twsrc%5Etfw">#BreastCancer</a> led to objective response rate (ORR) 21%, notably ORR 47% among pts w BRAC mutation on single arm ph 2 trial <a href="https://t.co/z5rmzX3F6k">https://t.co/z5rmzX3F6k</a> <a href="https://twitter.com/hashtag/BCSM?src=hash&amp;ref_src=twsrc%5Etfw">#BCSM</a>
&mdash; JAMA Oncology (@JAMAOnc) <a href="https://twitter.com/JAMAOnc/status/1139200760938455047?ref_src=twsrc%5Etfw">June 13, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><h2>Combination Exhibits Efficacy </h2>According to the study results, five patients had confirmed complete responses, five more had confirmed partial responses, 13 had stable disease, and 24 had progressive disease. Additional, in the efficacy-evaluable population (n&thinsp;=&thinsp;47), ORR comprised 10 patients (21%; 90% CI, 12% to 33%) and DCR included 23 patients (49%; 90% CI, 36% to 62%). The results further showed that median DOR was not reached at the time of the data cutoff, with seven patients still receiving treatment at the time of analysis.Moreover, 15 evaluable patients with tumor&nbsp;BRCA mutations, ORR comprised seven patients (47%; 90% CI, 24%-70%), DCR included 12 patients (80%; 90% CI, 56%-94%), with a median PFS of 8.3 months (95% CI, 2.1 months to not estimable). Further, 27 evaluable patients with&nbsp;BRCA&nbsp;wild-type tumors, ORR included 3 patients (11%; 90% CI, 3%-26%), DCR included 9 (33%; 90% CI, 19%-51%), and median PFS was 2.1 months (95% CI, 1.4-2.5 months).&ldquo;Of particular importance is that the combination treatment demonstrated clinical activity in patients irrespective of&nbsp;BRCA&nbsp;mutation or PD-L1 status, although the clinical activity is more pronounced in patients with tBRCAmut or those with PD-L1&ndash;positive tumors&rdquo;, the study researchers wrote.&ldquo;These data suggest that the combination of a PARP inhibitor and an anti&ndash;PD-1 antibody has a tolerable safety profile in patients with advanced or metastatic TNBC and promising antitumor activity, irrespective of&nbsp;BRCA&nbsp;mutation status,&rdquo; the researchers continued. &ldquo;To confirm the findings of this trial, further clinical development of niraparib in combination with PD-1 inhibition in larger-scale studies is under consideration.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Niraparib (PARPi) + pembro for metastatic <a href="https://twitter.com/hashtag/tnbc?src=hash&amp;ref_src=twsrc%5Etfw">#tnbc</a>: -Of 55pts, 10 with complete/partial response -49% disease control rate. -Most benefit was in BRCAmut patients
Congrats to the authors <a href="https://twitter.com/stolaney1?ref_src=twsrc%5Etfw">@stolaney1</a> <a href="https://twitter.com/FilipaLynce?ref_src=twsrc%5Etfw">@FilipaLynce</a> <a href="https://twitter.com/CareyAnders1?ref_src=twsrc%5Etfw">@CareyAnders1</a> <a href="https://twitter.com/melindatelli?ref_src=twsrc%5Etfw">@melindatelli</a><a href="https://twitter.com/hashtag/OncoAlert?src=hash&amp;ref_src=twsrc%5Etfw">#OncoAlert</a><a href="https://t.co/MQIZoGQmUk">https://t.co/MQIZoGQmUk</a>
&mdash; Daniel Stover, MD, FASCO (@StoverLab) <a href="https://twitter.com/StoverLab/status/1139365023233531904?ref_src=twsrc%5Etfw">June 14, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Early data but it is promising! Pembro+PARPi in TNBC. Could immuno actually work this time? Looking forward to an RCT to confirm this! <a href="https://t.co/eomqCRkSRl">https://t.co/eomqCRkSRl</a>
&mdash; Alex Friedlaender (@DralexGva) <a href="https://twitter.com/DralexGva/status/1139400463877459968?ref_src=twsrc%5Etfw">June 14, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Eric Bergson, MD

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

Latest News

Drug Combination Found Effective in the Treatment of Advanced Breast Cancer

Breast Cancer News

The combination of niraparib and pembrolizumab shows promising antitumor activity in patients with advanced metastatic triple-negative breast cancer (TNBC)

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe